We performed nonclinical studies supporting an investigational new drug (IND) application for the treatment of infantile Krabbe disease using an AAVhu68 vector expressing a codon-optimized GALC administered into the cisterna magna (NCT04771416). The gene discussed is GALC; the disease is Krabbe disease.